When compared to weight reductions of −14% with semaglutide, −8.4% with liraglutide, −10% with dulaglutide and −15% with tirzepatide in the general population, the authors concluded that the impact of GLP‐1 agonists may be attenuated in women with breast cancer receiving endocrine therapy [89]. Here, GLP1R is linked to breast carcinoma.